Objective: Passive administration of broadly neutralizing antibodies has been shown to protect against both vaginal and rectal challenge in the simian/human immunodeficiency virus (SHIV)/macaque model of HIV transmission. However, the relative efficacy of antibody against the two modes of exposure is unknown and, given differences in the composition and immunology of the two tissue compartments, this is an important gap in knowledge. To investigate the significance of the challenge route for antibody-mediated protection, we performed a comparative protection study in macaques using the highly potent human monoclonal antibody, PGT126.
Introduction
The mechanism of action for protection of most vaccines against human pathogens is believed to be elicitation of neutralizing antibodies (nAbs) and this is, therefore, also a highly sought after property in a vaccine against HIV [1] [2] [3] [4] . Indeed, numerous studies in macaques and humanized mice have shown that nAbs can provide sterilizing immunity against challenge with simian/human immunodeficiency virus (SHIV) and HIV [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . In particular, it has been shown that broadly neutralizing antibodies (bnAbs) can induce sterilizing immunity against mucosal challenge of SHIVs, which in addition to active vaccination also suggests a potential role for bnAbs in passive immunization strategies against HIV [5] [6] [7] [8] [9] [10] [11] [12] [13] 23 ].
Much has been learned about the conditions for HIV nAb protection against virus challenge in the last few years in both macaques and humanized mice. Antibody titration studies have indicated that sterilizing immunity is achieved at serum antibody concentrations in the approximate range of 10 to a few hundred-fold times in-vitro serum neutralizing titers [6, [9] [10] [11] 13, 16, 18, 21, 24, 25] . The precise numbers clearly depend upon the neutralization assay used but even allowing for this factor, there do appear to be some differences between different antibodies [5, 8, 10, 26] . To ensure infection of all of the control animals the viral inoculum in the studies quoted, 'high-dose' challenge experiments, are typically several logs higher than is generally observed in human semen [27] . Data from a repeated 'low-dose' SHIV/macaque challenge study showed protection at notably lower serum antibody neutralizing titers suggesting that sterilizing immunity in human exposure may be more readily achievable than predicted by the high-dose challenge studies [28] . Experiments, first in macaques and then in humanized mice have also indicated that Fc receptor-mediated activities contribute to the protective activity of bnAbs against HIV challenge [24, [28] [29] [30] . Furthermore, potent bnAbs have been shown to have dramatic effects on controlling virus in established infection, first in humanized mice, and then in macaques [31] [32] [33] .
Despite the advances, significant gaps remain in our knowledge of antibody protection against HIV, most notably the time and location of antibody interception of virus is not well understood. One study using an intravenous (i.v.) SHIV challenge showed that administration of a polyclonal preparation of nAbs 6 h but not 24 h after challenge conferred protection [22] . In mucosal transmission, this time dependence of antibody-mediated protection might be increased if systemic infection is preceded by local propagation and expansion in the vaginal or rectal tissues as has been proposed [34] [35] [36] . Interestingly, a recent study suggested that protection by a live attenuated simian immunodeficiency virus (SIV) vaccine correlated with local recruitment of glycoprotein (gp)41-specific IgG producing plasma cells in the vaginal tissue indicating a potential first line of defense by antibodies [37] .
In humans, the transmission rate through rectal exposure is at least 17 times higher than through vaginal exposure, which has been related to the immunology and architecture of the two tissues [35, 36, 38, 39] . At present, the relative efficacy of antibody against transmission via the two modes of exposure is unknown. One recent study compared the two mucosal challenge routes but only for a single dose of antibody and all animals in both groups were protected [10] . Here, by comparison of three bnAb doses against a single vaginal or rectal viral challenge we seek to investigate whether the route of viral transmission strongly influences the efficacy of antibody-mediated protection in rhesus macaques.
Methods

Macaques
The study was carried out in strict accordance with the recommendations in the 'Guide for the Care and Use of Laboratory Animals' of the National Institutes of Health (NIH). The protocol for the vaginal challenge study was approved by the Institutional Animal Care and Use Committee of Bioqual Inc. and Beth Israel Deaconess Medical Center. The protocol for the rectal challenge study was approved by the Institutional Animal Care and Use Committee of Emory University. A total of 35 animals were used, 19 in the vaginal challenge experiment (five animals per human antibody PGT126 treatment group, four control animals) and 16 in the rectal challenge experiment (four animals per PGT126 treatment group, four control animals). All antibody infusions, viral challenges, and sample collections were performed under ketamine or ketamine/telezol-induced anesthesia, and all efforts were made to minimize suffering. Virus challenge and i.v. antibody protocols are described elsewhere [6, 7] . Briefly, antibodies were infused slowly in the saphenous vein 1 day prior to viral challenge. Intrarectal challenge was performed on animals placed in a prone position with the hips supported. The viral inoculum was delivered atraumatically by a syringe inserted approximately 4 cm into the rectum. Following procedure, the syringe was examined for any sign of blood, which would indicate mucosal trauma. The animals were returned to their cages in a prone position (to prevent leakage of viral inoculum) and allowed to recover. Intravaginal challenge was performed on animals with the perineum slightly elevated. The viral inoculum was delivered atraumatically using an eight French pediatric feeding tube attached to a syringe barrel. The animals were maintained with the perineum slightly elevated for 15 min before being returned to their cages and allowed to recover. All animals were monitored at least once daily for evidence of pain or distress. Plasma and serum samples were obtained throughout the studies and analyzed for viral load, PGT126 concentration and serum neutralizing titer. Animals in the vaginal challenge experiment were given 30 mg medroxy-progesterone (Depo-Provera) i.m. 28 days prior to the day of challenge to thin the vaginal tissue and synchronize menstrual cycles. At the start of the experiments, all animals were experimentally naive and were negative for antibodies against HIV-1, SIV, and type D retrovirus. All animals were negative for the Mamu-B Ã 08 and Mamu-B Ã 17 alleles associated with spontaneous virologic control. Eight of the intrarectally challenged animals were Mamu-A Ã 01 positive and were evenly distribution across treatment groups.
Challenge virus
The challenge virus was the tier 2 SHIV SF162 passage 3 virus and was propagated in phytohemagglutininactivated rhesus macaque peripheral blood mononuclear cells (PBMC). The original stock was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH (catalog number 6526; contributors Drs J. Harouse, C. Cheng-Mayer and R. Pal). The challenge dose was 300 Tissue Culture Infective Dose (TCID) 50 for both exposure routes.
Antibody production
Antibody production was carried out as previously described [29, 40] . In brief, antibodies were generated in Chinese hamster ovary-K1 cells and purified by protein A affinity chromatography. PGT126 is a bnAb which recognizes the high-mannose patch on HIV gp120 [40] [41] [42] . Dengue (DEN)3, a dengue virus nonstructural protein1-specific antibody was used as the isotype control antibody in the animal studies. Antibodies contained less that 0.03 EU/mg endotoxins.
ELISA
Serum PGT126 concentrations were determined by a HIV JRCSF gp120-specific ELISA as previously described for HIV JRFL gp120 [6] . In brief, 96 well microplates were coated with 2 mg/ml recombinant HIV JRCSF gp120 overnight. Following a wash and blocking step, serial dilution of serum samples, or purified antibodies were added to the plate. After incubation and a wash step, binding was detected with a goat antihuman IgG fragment antigen-binding 2 fragment coupled to alkaline phosphatase (ThermoFisher Scientific, Waltham, Massachusetts, USA) and visualized with p-nitrophenyl phosphate substrate (Sigma-Aldrich, St. Louis, Missouri, USA).
Neutralization assay
Antibody and serum neutralization titers were determined using the TZM-bl assay as previously described [43] . In brief, virus and antibodies/serum were mixed and incubated for 1 h before being added to TZM-bl cell in 96 well plates. Diethylaminoethanol (DEAE)-Dextran was added at a final concentration of 10 mg/ml (Sigma-Aldrich). Forty-eight hours after infections, cells were lysed and luciferase expression was quantified using the Bright-Glo Luciferase Assay System (Promega, Madison, Wisconsin, USA). Pseudovirus was generated in 293T cells and SHIV SF162P3 was propagated in phytohemagglutinin-activated rhesus macaque PBMC.
Statistical analyses
Rectal and vaginal challenges were compared by Fisher's exact test [44] using GraphPad Prism 6 software package (GraphPad, San Diego, CA, USA) and by logistic regression analysis using SAS, version 9.2 (SAS, Cary, NC, USA). Power analysis for the Fisher's exact test as implemented in R statistical package (http://rpackages.ianhowson.com/cran/statmod/man/power.html).
Results
PGT126 potently neutralizes the challenge virus SHIV SF162P3 in vitro
Prior to carrying out an in-vivo protection study using the bnAb PGT126, we determined the in-vitro potency of the antibody against the challenge virus strain SHIV SF162P3 . For comparison, we included PGT121 and b12, two antibodies previously tested in protection studies against this virus [6, 9] . The TZM-bl-based neutralization assay was performed using both single round pseudovirus and full-length replication competent virus (the challenge stock). In the pseudovirus assay, PGT126 had an inhibitory concentration (IC) 50 of 0.03 mg/ml, whereas PGT121 and b12 had IC 50 s of 0.01 and 0.1 mg/ml, respectively (Fig. 1a ). In the replication competent assay, PGT126 had an IC 50 of 0.3 mg/ml, whereas PGT121 and b12 had IC 50 s of 0.03 and 1.6 mg/ ml, respectively (Fig. 1b ). The two assays demonstrated that PGT126 neutralized SHIV SF162P3 with a potency between that of PGT121 and b12.
PGT126 protects against vaginal and rectal challenge of SHIV SF162P3 with comparable efficiency in vivo
To compare antibody-mediated protection against vaginal and rectal challenge, we performed a three-dose PGT126 titration protection study. The antibody doses were the same for the vaginal and rectal challenged groups and the animals received either 10 mg/kg of PGT126, 2 mg/kg of PGT126, 0.4 mg/kg of PGT126 or 10 mg/kg of an isotype control antibody. Antibodies were administered 24 h prior to a single challenge of SHIV SF162P3 . The challenge dose, based on a previous in-vivo titration of the virus stock, was chosen as the lowest dose that would enable infection of all control animals. Comparable levels of protection were observed for vaginally and rectally challenged animals administered the same dose of PGT126 (Fig. 2) . In the vaginally challenged animals, sterilizing immunity (defined here as no detectable viremia) was observed in all animals administered 10 mg/kg of PGT126, in three out of five animals administered 2 mg/kg of PGT126 and in one out of five animals administered 0.4 mg/kg of PGT126 ( Fig. 2a ). In the rectally challenged animals, sterilizing immunity was observed in three out of four animals administered 10 mg/kg of PGT126, in two out of four animals administered 2 mg/kg of PGT126 and in none of the four animals administered 0.4 mg/kg of PGT126 (Fig. 2b) . Regardless of the challenge route, all animals administered the isotype control antibody became infected as expected. Comparison by Fisher's exact test and logistic regression analysis showed no statistically significant association between protection and the type of the challenge for any of the antibody dose groups (See Supplementary Information text for discussion and limitations of statistical analysis, http://links.lww.com/ QAD/A911).
Serum concentrations and neutralizing titers were comparable between vaginally and rectally challenged animals administered the same antibody dose Serum samples were analyzed at the time of challenge and PGT126 concentrations at the different dose levels were in similar ranges for the two sets of challenge experiment as expected ( Fig. 3) . Based on the longitudinal serum concentrations, an in-vivo half-life in rhesus macaques for PGT126 was determined by fitting the slope to a one phase exponential decay (starting on day four to account for initial distribution). A combined half-life was calculated to be 6.3 days having slightly higher numbers in the rectally challenged animals (averaging 7.1 days) compared with vaginally challenged animals (averaging 5.5 days).
Using the TZM-bl assay, serum neutralization titers were determined at the time of challenge and up to 7 days after challenge (Table 1) . At the time of challenge, average serum neutralizing IC 50 titers (reciprocal dilution) for the vaginally challenged animals were 2017, 251, and 56 for the 10, 2, and 0.4 mg/kg groups, respectively, whereas the average serum neutralizing IC 50 titers (reciprocal dilution) for the rectally challenged animals were 2448, 509, and 73 for the 10, 2, and 0.4 mg/kg, respectively. Serum concentrations and serum neutralizing titers corresponded very well as the calculation of a serum IC 50 concentration of PGT126 showed an average serum IC 50 of 0.06 mg/ml (serum concentration divided by the serum dilution resulting in 50% inhibition) compared with 0.03 mg/ml obtained using purified PGT126 (Fig. 1a) . Together, the data demonstrate comparable pharmacokinetics between the vaginally and rectally challenged animals administered the same antibody dose.
Discussion
Passive transfer of bnAbs has been shown to protect rhesus macaques against both vaginal and rectal SHIV challenge [5] [6] [7] [8] [9] [10] [11] 13] . However, the two tissue compartments vary considerably and to our knowledge, no study has directly addressed whether the challenge route strongly impacts the protective potency of bnAbs. Using the bnAb PGT126, we performed an antibody dose titration experiment against vaginal and rectal challenge of SHIV SF162P3 in rhesus macaques and found no significant difference in the protective ability of the antibody against the two challenge routes. We note that we used a relatively large number of animals (35 animals) to make this finding. To unambiguously prove that the protection Fig. 2 . Plasma viral loads in macaques passively administered PGT126 or DEN3 mAbs before being challenged with a single dose of SHIV SF162P3 . (a) Plasma viral loads for animals challenged vaginally 24 h after being administered 10 mg/kg of PGT126 (green), 2 mg/kg of PGT126 (black), 0.4 mg/kg of PGT126 (blue), or 10 mg/kg of the isotype control DEN3 (red). All animals receiving 10 mg/kg were protected and showed no detectable viremia, three out of five became infected in the 2 mg/kg treatment group and four out of five became infected in the 0.4 mg/kg treatment group. (b) Plasma viral loads for animals challenged rectally 24 h after being administered 10 mg/kg of PGT126 (green), 2 mg/kg of PGT126 (black), 0.4 mg/kg of PGT126 (blue), or 10 mg/kg of the isotype control DEN3 (red). One out of four animals receiving 10 mg/kg became infected, two out of four became infected in the 2 mg/kg treatment group and four out of four became infected in the 0.4 mg/kg treatment group. All animals given the isotype control antibody became viremic regardless of being vaginally or rectally challenged. Viral detection limit was 50 and 60 copies/ ml for the vaginal and rectal challenge experiments, respectively. SHIV, simian/human immunodeficiency virus.
is identical for the two challenge routes would require a much larger number of animals, 100þ macaques (Supplementary Information text, http://links.lww.com/ QAD/A911).
Evidence suggests that rectal exposure to HIV contains a higher risk of viral transmission and faster viral dissemination than vaginal exposure, which has been associated with significant differences between the two tissues [35, 36, 38, 39] . However, the exact time and place for antibody interception of virus is not known. If the 'window of opportunity' for preventing infection is considered to be during the initial replication and expansion in the mucosal tissue [39] then our results are consistent with a similar antibody biodistribution between vaginal and rectal tissues. A direct investigation of these tissues was beyond the scope of the present study because of the number of animals available. However, recent studies do suggest that the level of antibody is roughly similar in vaginal and rectal tissues following i.v. administration and should, therefore, in principle be equivalently available in both tissues for neutralizing incoming virus [11, 12] . Infused antibodies can also be detected in mucosal secretions but the levels appear to be less consistent than those found in tissues and the sampling process entails a risk of bleeding, and thereby a potential higher risk of infection [6, 8, 9, 12, 13, 23, 32, 45] . Our results are equally consistent with bnAb interception of the virus occurring beyond initial replication in the mucosal tissue, for example, in the blood or lymphatic system when the challenge route would be anticipated to have a minimal role. However, it is worth noting that systemically administrated neutralizing antibodies can prevent viral infection of mucosal tissue as shown in several animal models of Human papillomavirus infection [46, 47] indicating significant transfer of antibodies between the two compartments. Overall, further studies looking directly at the location of both antibody and virus following coadministration/challenge are needed to clarify the location of antibody interception of virus. 
Neutralizing titers, IC50
A caveat of the present study worth considering is the use of Depo-Provera in the vaginally challenged animals. The vaginal epithelium of rhesus macaques is much more keratinized than humans and Depo-Provera treatment, in addition to synchronizing the menstrual cycle, thins the epithelium, reportedly to similar levels of thickness observed in the human luteal phase [48, 49] .
The main concern about using Depo-Provera in passive antibody transfer studies has been that the epithelium is so thinned that the virus can transmit more easily than in human exposure. However, the applied dose (mg/kg) is in the range of that given for contraceptive use in humans and the number of transmitted/founder viruses does not appear to be increased in Depo-Proveratreated animals compared to that observed in humans [48] [49] [50] [51] . In addition, without hormonal treatment the challenge dose would need to be increased substantially from a dose (300 TCID 50 ) already 1-2 logs higher than the range normally seen in human semen [27, 48] .
Overall, we believe that the Depo-Provera model serves as the best compromise for this study but realize that it entails a risk of underestimating the barriers for vaginal transmission.
PGT126 is part of the group of bnAbs that recognizes the high-mannose patch centered around the glycan at position N332 on gp120 [40] [41] [42] 52, 53] . PGT121 is also a member of this group and we recently showed efficient protection against vaginal challenge as well as strong suppression of viremia in an established infection [9, 31] . The in-vitro activity of PGT126 against the SHIV SF162P3 challenge virus is 10-fold lower than PGT121 (Fig. 1b) . This difference in vitro correlated well with the difference we found in the in-vivo activity of the two antibodies.
In the present study, PGT126 protected three out of five animals against vaginal challenge at an administered antibody dose of 2 mg/kg ( Fig. 2a) whereas, in our previous study, PGT121 protected the same number of animals (three out of five) at a 10-fold lower administered antibody dose of 0.2 mg/kg [9] . In the present study, average serum neutralizing titers of 251 and 509 protected 60% (three out of five) of the vaginal challenged animals and 50% (two out of four) of the rectal challenged animals, respectively. These numbers correlate well with our PGT121 passive protection study as an average serum neutralizing titer of 285 protected 60% (three out of five) of the animals challenged vaginally with SHIV SF162P3 [9] . Two other studies, one a comprehensive study based on rectal challenge of 60 macaques, have used a probit regression model to calculate that serum neutralizing titers of 104 and 235 would be protective of 50% of the challenged animals [11, 25] . It should be noted that these analysis were based on virus pseudotyped with the challenge virus' envelope and not the challenge virus itself. Nevertheless, collectively these studies strongly suggest, as previously stated [9, 11] , that protective titers against HIV may be achievable if elicitation of antibodies with similar potencies as the ones used in these studies can be achieved by vaccination.
In conclusion, our findings noted no major differences in the ability of the bnAb PGT126 to protect against vaginal or rectal challenge in the SHIV/macaque model. The results are consistent with the notion that bnAbs, either induced by vaccination or used as immunoprophylaxis, will have broadly similar efficacy against both primary transmission routes for HIV.
